Ensysce Biosciences Inc. (ENSC) - מזומן למניה

סמל תאגידי ולוגו של Ensysce Biosciences Inc. (ENSC)

Ensysce Biosciences (ENSC) is developing innovative TAAP/MPAR systems to combat the opioid crisis. Ownership of patents for safe analgesics provides high growth potential. However, the lack of sales leaves the company dependent on external financing and FDA verdicts. The cash per share metric illustrates liquidity dynamics, where the 1.53 mark indicates the level of current capital reserves.

Ensysce Biosciences (ENSC) - מזומנים למניה מ-04.07.2022 עד 20.11.2026

פילוחים אנליטיים של חברת Ensysce Biosciences

- שווי מניות ותחזית קונצנזוס למחירים:
- פרטי פוזיציית מזומנים ותזרימי מזומנים:
ניתוח מקיף של החברה:Ensysce Biosciences
מוצר המיוצר על ידי Ensysce Biosciences, Inc.

The development of safe TAAP analgesics requires significant capital expenditures for clinical trials. By analyzing the cash per share chart, an investor assesses the liquidity of Ensysce Biosciences (ENSC). This metric is calculated as the ratio of total cash to the total number of shares outstanding. It determines the actual asset value available to each share. A high level of this indicator guarantees the biotech's financial stability during the period leading up to product commercialization.